1. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
   Xiao-Feng Dong et al, 2018, Clinical Cancer Research CrossRef
2. Computationally guided high-throughput design of self-assembling drug nanoparticles
   Daniel Reker et al, 2021, Nature Nanotechnology CrossRef
3. COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers
   Paul Rodrigues et al, 2024, Medical Oncology CrossRef
4. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway
   Wenliang Tan et al, 2017, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics CrossRef
5. PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells
   Jiunn-Chang Lin et al, 2021, International Journal of Molecular Sciences CrossRef
6. Downregulation of glucose-regulated protein 78 enhances the cytotoxic effects of curcumin on human nasopharyngeal carcinoma cells
   Xiaoming Yu et al, 2018, International Journal of Molecular Medicine CrossRef
7. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement
   Shuangshuang Li et al, 2020, Biomedicine & Pharmacotherapy CrossRef
8. Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility
   Xuan-Ke Ji et al, 2021, World Journal of Gastroenterology CrossRef
9. Endoplasmic reticulum stress in liver diseases
   Amir Ajoolabady et al, 2023, Hepatology CrossRef
10. Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma
    Yinghong Zhou et al, 2020, Oxidative Medicine and Cellular Longevity CrossRef
11. Endoplasmic reticulum stress: Multiple regulatory roles in hepatocellular carcinoma
    Jiacheng Wu et al, 2021, Biomedicine & Pharmacotherapy CrossRef
12. Fe 3+ -binding transferrin nanovesicles encapsulating sorafenib induce ferroptosis in hepatocellular carcinoma
    Youmei Xiao et al, 2023, Biomaterials Research CrossRef
13. In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol
    Agnieszka Karbownik et al, 2020, Biomedicine & Pharmacotherapy CrossRef
14. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway
    TAO LI et al, 2016, Oncology Reports CrossRef
15. Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals
    Jingtao Zhong et al, 2018, International Journal of Molecular Medicine CrossRef